About Soligenix
Soligenix is a company based in Princeton (United States) founded in 1987.. The company has 16 employees as of December 31, 2024. Soligenix offers products and services including HyBryte, SGX302, SGX942, SGX945, and SGX203. Soligenix operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Princeton, United States
- Employees 16 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Soligenix, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-8.27 M-34.62as on Dec 31, 2024
-
EBITDA
$-9.55 M-13.46as on Dec 31, 2024
-
Latest Funding Round
$2.6 M (USD), Grant
Sep 12, 2022
-
Investors
NIH
& 13 more
-
Employee Count
16
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Soligenix
Soligenix is a publicly listed company on the NASDAQ with ticker symbol SNGX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Soligenix
Soligenix offers a comprehensive portfolio of products and services, including HyBryte, SGX302, SGX942, SGX945, and SGX203. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for cutaneous T-cell lymphoma in rare disease applications
Treatment for mild to moderate plaque psoriasis
Therapy for oral mucositis in medical conditions
Treatment for aphthous ulcers associated with Behçet’s disease
Therapy for pediatric Crohn’s disease
Vaccine to prevent ricin poisoning in biodefense
Unlock access to complete
Unlock access to complete
Funding Insights of Soligenix
- Total Funding Total Funding
- Total Rounds 24
- Last Round Grant — $2.6M
-
First Round
First Round
(20 Jan 2009)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2022 | Amount | Grant - Soligenix | Valuation |
investors |
|
| Jun, 2021 | Amount | Grant - Soligenix | Valuation |
investors |
|
| Dec, 2020 | Amount | Grant - Soligenix | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Soligenix
Soligenix has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and U.S. Food and Drug Administration. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pontifax Venture Capital is focused on life sciences investments.
|
Founded Year | Domain | Location | |
|
Late-stage venture capital is provided to US life sciences companies.
|
Founded Year | Domain | Location | |
|
Investments are focused on life science and healthcare innovations.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Soligenix
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Soligenix
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Soligenix Comparisons
Competitors of Soligenix
Soligenix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Soligenix
Frequently Asked Questions about Soligenix
When was Soligenix founded?
Soligenix was founded in 1987 and raised its 1st funding round 22 years after it was founded.
Where is Soligenix located?
Soligenix is headquartered in Princeton, United States. It is registered at Princeton, New Jersey, United States.
Who is the current CEO of Soligenix?
Christopher Schaber is the current CEO of Soligenix.
How many employees does Soligenix have?
As of Dec 31, 2024, the latest employee count at Soligenix is 16.
What does Soligenix do?
Soligenix (formerly DOR BioPharma) develops small molecule therapeutics for rare diseases. Its most advanced candidate is in phase III trials for cutaneous T-cell lymphoma and has received both orphan designation and fast track status for the same. In addition, the company has two candidates in phase II trials for Crohns disease and oral mucositis in head and neck cancer, and a candidate for radiation enteritis in phase I trials. Soligenix also has a pipeline of vaccines for Ricin toxicity, GI acute radiation syndrome, and melioidosis.
Who are the top competitors of Soligenix?
Soligenix's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Soligenix offer?
Soligenix offers HyBryte, SGX302, SGX942, SGX945, and 2 more products and services.
Is Soligenix publicly traded?
Yes, Soligenix is publicly traded on NASDAQ under the ticker symbol SNGX.
Who are Soligenix's investors?
Soligenix has 14 investors. Key investors include NIH, HHS, U.S. Food and Drug Administration, NJEDA, and Pontifax Venture Capital.
What is Soligenix's ticker symbol?
The ticker symbol of Soligenix is SNGX on NASDAQ.